Genitourinary Cancers   

Questions discussed in this category

Given the limited # of patients with PALB2 mutation on the PROfound trial (de Bono et al., PMID 32343890) and the benefit primarily driven by Cohort A...

Assume patient has normal renal function, is not a surgical candidate, and kidney is the only site of disease.

Would a specific Gleason score, age, pathological feature, or PSA be an indication for covering the pelvic nodes? Would giving concurrent ADT affect y...

For higher risk patients, eg PSA >0.5 or high risk gleason score, etc, would you consider dose escalation still? Prior data had suggested benefit t...

STAMPEDE answer is yes, intuitively it seems there must be a line somewhere though. For patients staged only with PET that is widely M1, should a CT ...

Are there specific patients where you're more apt to continue versus holding IO while continuing TKI?

The FLAME trial demonstrated a significant improvement in 5-year DFS, without any significant changes in overall toxicities, when patients being treat...

What dose and fractionation do you utilize? Would your recommendations differ considering the site of disease is at the penile base/suprapubic region?

NCCN, NRG contouring guidelines, and NRG-GU-009 all recommend treating non-metastatic high risk prostate cancer with dose escalation to involved gross...

If a patient had a PSA > 15, PI-RADS 5 and lesions on MRI, would you treat without a biopsy? 

Per the NCCN guidelines and clinical trials, the patient does not fit the criteria for low metastatic burden, and therefore the benefit of radiation t...

Would you offer brachytherapy boost after EBRT? Is there concern for needle tract seeding with brachytherapy? 

GETUG-AFU 18 has shown a survival benefit over 70 Gy. There is much pressure to hypofractionate, but this is the first study showing a survival benefi...

Testicular imaging was negative for suspicious mass. Would you treat the bilateral testes with radiation in addition to the PA field? Would you treat ...

Patient has multiple adverse features on pathology, however, PSA just became detectable one year after surgery. SPPORT included patients with PSA>0...

KEYNOTE-564 required CrCl 30 or above. Not having a baseline/stable CrCl may make it difficult to diagnose or treat IO nephritis. 

Do you use decipher, or other genetic testing to determine whether you will include pelvic lymph nodes when you give definitive EBRT? Can you comment ...

Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

For example, a patient that received an MRI after biopsy that demonstrates a PIRADS 5 lesion in anterior TZ which likely was not sampled on biopsy. Wo...

Data for SBRT for RCC is promising but there is increasing literature on microwave ablation, radio frequency, and cryoablation. Are there any distinct...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...

Assume non regional nodes are non pathological by size. Patient also has pelvic nodes that are positive. Would you consider this low metastatic burd...

Which patients specifically benefit from both mpMRI and PET-PSMA?

In non-FGFR mutated patients, would you use cisplatin/gemcitabine or sacituzimab govitecan at this point?

Are there any precautions or pre-medications that may permit this treatment in patients who are fit for therapy but have exhausted all other treatment...

How would it change your risk group or management? Does Decipher help further inform treatment?

What characteristics? TURP? AUA? Size of prostate? How do you change your fractionation?

Many options for vasomotor symptoms of menopause do not work well for men on ADT. However, fezolinetant is a neurokinin B blocker, so theoretically, s...

Assume slowly rising PSA in a low risk prostate cancer patient with negative PSMA PET CT. If so, what dose and what would you cover? If not, when woul...

Would you use either as monotherapy or boost in appropriate candidates (favorable IPSS, safe for anesthesia)? Assuming IPSS < 15 or 20 and minimal ...

I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...

Intravesical therapy was delivered two years prior, and last cystoscopy was negative. One-third of the bladder would otherwise be included in the plan...

Assume this is a male, treating to 55 Gy in 20 fx.

A patient had limited metastatic prostate cancer several years ago and was treated with orchiectomy only, and recently had Xtandi added. PSA remains d...

Does this option need to be added to NCCN guidelines? How does the type of brachytherapy, HDR vs LDR, influence your recommendations? Does ADT play a ...

When (if ever) would you consider immune checkpoint inhibitor up front? Would you be less inclined to offer triple drug therapy? (Some thought that ta...

This would be for the "locally advanced unresectable" indication. Consider an older patient who is not eligible for NAC nor TMT due to nodal disease a...

Are there any chemotherapy regimens that can be used in elderly patients with poor PS who are not candidates for BEP?

What is the risk of renal artery stenosis causing malignant hypertension and at what dose does this become an issue?

Do you typically recommend SBRT? What dose? Or do you ever recommend surgery or surgery followed by XRT?

At 2023 ASTRO, PACE-B reported very low 5-year RTOG grade 2+ rectal toxicity with SBRT (1/363) and conventionally or moderately fractionated radiother...

If baseline testosterone is at castrate levels (e.g. <50), would you consider patient to have castrate-resistant disease?

For instance, do you factor availability of RNAseq, inclusion of normal blood controls, and QNS rates into your decision?

How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-c...

MASTER analysis showed 30 - 40% perisalvage ADT use. What group of patients do you consider for ADT? And for what duration?

Do you treat in this scenario if mild/moderate infiltration? What are your thoughts on the article by Fischer-Valuck et al., PRO, 2017 (PMID 28089528)...

STAMPEDE arm H uses the CHAARTED definition for bone metastases in the axial skeleton. There is no mention of patients with non-regional nodes. Would ...

Galsky criteria are for metastatic disease, can they be relaxed in localized MIBC setting given curative intent of therapy? 

In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...

What volumes would you encompass? Anything different than standard nodal basins for high risk prostate cancer?

In the setting of EBRT alone, a "FLAME"-style boost may increase bPFS. Does anyone have experience with increasing the EBRT dose in combination EBRT+L...

He cannot sense bladder fullness but has no incontinence. Intermittently he urinates by increasing intra-abdominal pressure resulting in a good stream...

RADICALs used >0.1 and rising or 3 consecutive rising PSA levels regardless of absolute value. RAVES and GETUG-AFU 17 used >0.2. 

If so, how do you determine which of the lesions constitutes the "dominant" lesion to boost? Alternatively, do you treat all noted lesions with SIB, ...

For example do you use Prolaris, or other genetic tests to guide ADT decision making? 

Assume recurrence is biopsy proven. Would you ever consider focal vs whole gland brachytherapy? 

Assume this patient had resection with N2/N3 disease. Would you recommendations change if this was N1? Any other factors that weigh in on primary site...

If an otherwise healthy male patient in his 70s has Gleason 4+4 disease in 7/12 cores and left sided internal iliac nodes, but refuses any form of end...

Patients in their later 40s with favorable intermediate-risk prostate cancer s/p 7000cGy/28 EBRT only.

For example, reducing coverage to 95% of Rx within a large median lobe for an intermediate risk prostate cancer case with no gross disease near base t...

SBRT vs more comprehensive nodal RT with SIB to involved node? Would you include the prostate bed in your treatment volume? ADT duration? What other f...

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...

Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...

For example: radiation fractionation schedule, modality (proton, MRI linac, cyberknife, etc), risk categorization, prostate size, history of IBS, hist...

Would gene expression testing (e.g., Decipher, Prolaris, Oncotype DX) guide your management recommendations?

Patient has contraindication to MRI but otherwise has what seems to be a favorable intermediate risk prostate cancer

Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...

I have a healthy 70+ year old man recently diagnosed with cT3N1M0 rectal adenoCA and GS 3+4=7 prostate cancer in 1/6 cores with a PSA of 25. Is ...

What sort of factors (post-op PSA level, time to biochemical failure, Gleason score, etc.) help guide your decision making? In general, when do you c...

If so, how? The trial did not exclude patients who had prior radiation (except hemibody RT) but there is little information on how to estimate dose to...

Would a higher Decipher score, despite low risk for nodal disease based on MSKCC nomogram or Roach formula, encourage you to treat the pelvic lymph no...

Is the patient permanently at elevated risk for rectourethral fistula with rectal biopsy? Do you have any threshold for the GI to biopsy a rectal lesi...

A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...

Specifically if metastatic risk estimate approached the failure rate in control arm of STAMPEDE for high-risk non-metastatic disease (69% MFS at 6 yea...

Please specify how your institution is allocating resources now or will be soon.

Would you recommend elective nodal radiation and sequential boost to the node? What dose? Would you recommend treatment similar to OLIGOPELVIS-GETUG P...

Based on GI regimen or urothelial carcinoma regimens?

Would you biopsy lymph node to confirm recurrence/histology?  If confirmed, how do you decide between RT vs chemotherapy? If chemo - BEP x3 vs E...

There is a recent publication that nicely summarizes the molecular/genetic tests for prostate cancer (Ross et al., PMID 26123120). What should be done...

Assume the patient is not a candidate for surgery. What dose would you use? Would you recommend a lower dose to not damage the patient's kidney functi...

What patient factors do you consider to decide between 55 Gy/20 fx and 64 Gy/32 fx with or without nodal irradiation? What if your patient is younger ...

If the patient received <2 months of immunotherapy, would you continue immunotherapy alone or transition to enfortumab monotherapy or EV+Pembro?

What special considerations or precautions would you keep in mind when considering re-irradiation? The prior radiation was post prostatectomy RT. ...

What imaging modality do you use (conventional, PSMA PET, etc.)? When do you image (ex: a PSA threshold or PSADT)?

For example, transperineal biopsies may capture a higher volume of disease. Should this change risk stratification compared to transrectal biopsies? I...

The protocol for the James trial (NEJM 2012) states: "non-target tissue may be excluded at the discretion of treating physician." For gyn applications...

This same patient has Grade Group 5 disease with extraprostatic extension and a positive margin with pre-operative PSMA PET/CT negative for regional o...

If so, is there a particular volumetric threshold you use before a patient gets onto the sim or treatment table?

For example, a patient with PSA < 10 and low volume Gleason 4+4=8 disease. Would you consider 6 months vs. 18 months vs. 2 years?

Do you use CT, MRI or PET/CT to create GTV volumes? What margins do you use for your CTV/PTV? 

For example, if patient had Gleason 4+5 on biopsy but Gleason 4+3 with Tertiary Grade 5 on final pathology? Would you consider intensifying their horm...

If the location of the biochemically evident cancer cannot be determined, would you re-irradiate the prostate despite absence of histologic proof of l...

Would you consider using an IO-based treatment or move on to TKI? Does the presence of sarcomatoid or rhabdoid features impact your approach?

Would you biopsy the metastatic lesion? Would you treat prostate definitively and monitor closely? Would you treat prostate and oligosites?

Assume SSD at isocenter is correct. When are you concerned about the dose to PTV or OARs? Article below appears to say minor effect. Zhang et al....

RADICALS-HD trial (ESMO 2022) demonstrated metastasis free survival benefit with 24 months compared to 6 months of ADT.

Would you treat the entire pelvis vs local recurrence? How would you approach the oligometastatic lesion? Would your treatment recommendation change i...

Cancer was with mesonephric features, and was originally within a urethral diverticulum. Would you consider RT vs chemoRT vs surveillance?

This may impact decisions on brachytherapy boost and/or use of ADT since MRI-guided samples may skew patients into the unfavorable risk category

If a patient with prostate or bladder cancer has irritative  bladder symptoms during IGRT and urinalysis reveals microscopic hematuria, WBCs, but...

Is there an extent of nodal involvement in prostate cancer above which you would not offer definitive XRT? With PSMA/PET we see some patients with inc...

Would you recommend chemoRT and take the whole bladder to full dose  or do you only boost the invasive disease?

Assume a life expectancy of approximately 5-10 years. What factors would influence your consideration of intermittent ADT vs. watchful waiting?

Are you waiting for BCG to become available or are you using other bridging therapies such as pembrolizumab?

Do you wait for radiographic progression? What is your preferred imaging modality for re-staging?

How do you decide between downstaging chemotherapy or upfront concurrent chemoradiotherapy? Both are listed as NCCN options. 

If a patient who has undergone radical prostatectomy many years previously presents with biochemical failure and is found to have a nodule in the pros...

Assume a young, fit patient who has not had prior pelvic RT before, and has been fully staged with molecular imaging (e.g., PSMA) with no evidence of ...

For a patient, who has received SBRT & WBRT for CNS disease, is there a role of autoSCT and HD-chemo in this setting (no residual extra-CNS diseas...

Current NCCN guidelines recommended not combining relugolix with these agents until more data is available.  Any drug interaction concerns or ot...

Specifically, in the TZ and PZ? What references do use for prostate nodule boost as done in FLAME trial?  Hypointensities are contoured on T2W M...

General recommendations on dose and management presuming unresectable. 

Would surgical margins, evidence of angiolymphatic spread, number of lymph nodes removed during surgery inform your decision? 

If the patient has had prior prostate radiation and is not a surgical candidate, would you treat with systemic therapy alone? What is the natural his...

Confirmed no urothelial carcinoma and muscle in specimen without involvement. 

Would you avoid combination with TKI given possible higher risk of osteonecrosis of the jaw?

Would increased risks from concurrent intravitreal avastin preclude treatment? Would you recommend a waiting period in between the treatments?

How high would you try to boost those involved nodes if they are in a favorable location with respect to his rectum and small bowel? 

Do you sim and treat with their bladder as is? Or do you have patients who do urinate fill their bladder somewhat? Fluid overload is often a considera...

PSMA showed no distant or regional disease but did show a prostatic recurrence.

Is there a reason to choose Pylarify (piflufolastat F 18) or Gallium 68 PSMA-11? If so, are there different rates of detection? Are there logisti...

What factors influence whether you treat an elective nodal volume vs gross nodal volume (plus a small margin) in the setting of oligometastatic or oli...

If so, what dose constraint do you follow and how do you contour the bladder neck?

Is there concern for increased toxicity from erdafitinib following avelumab similar to osimertinib toxicity following pembrolizumab in NSCLC? Does FGF...

Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?

If so, do you use it for all patients or only cisplatin doses >= 70 mg/m2? What dose of mannitol do you use?

Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT. 

FLAME used an atypical fractionation scheme of 77 Gy in 35 fractions boosting MRI defined nodule to 95 Gy. Would you consider a 20-fraction or 28-frac...

Or would you proceed with cabazitaxel or other therapy? Initial chemo-hormonal therapy was ADT + Docetaxel x6 cycles.Docetaxel rechallenge at time of ...

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?

Do you allow this finding to change your management, or ignore it, as the "lesion" was not malignant?

For example, in a patient on steroids for CNS or spinal metastases - would you use IO-IO vs IO-TKI or TKI monotherapy?

If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

How soon is too soon after surgery to check PSA?

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

When treating intact bladder case to 63-64.8 Gy with shrinking fields, the max bowel dose is close to the rx dose. Old RTOG trials often just used V45...

In addition to scans, would you biopsy the prostate/SV? Would radiation therapy to the untreated pelvic nodes with hormonal therapy be a consideratio...

Does the TURP defect in the prostate affect efficacy or toxicity or SBRT?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

NCCN states to consider adjuvant chemotherapy similar to muscle invasive bladder cancer in this scenario, but one would avert adjuvant chemotherapy in...

Is there a specific brand or formulation you prefer? The literature supporting the use of probiotics does not standardize the type or dose of probiot...

Would you use it for initial staging or at time of biochemical recurrence?

What do you tell men who want to know if their testosterone has recovered?

If the diagnosis was made by an outside physicain, how do you confirm/refute the diagnosis? Would an alternative diagnosis like a thrombosed hemorrhoi...

For example, for a biochemically recurrent patient now with 4 PSMA PET+ nodes, if one of those PSMA+ pelvic nodes is within the prior field and adjace...

Recent data from Spratt has suggested improved outcomes with concurrent vs neoadjuvant ADT. However, during the first 1-2 months there is expected pro...

If radiation, what type? EBRT or brachytherapy? Any other techniques you would recommend, such as rectal balloon? 

The Intergroup 0162 trial did not demonstrate noninferiority, although OS difference only 5.1 vs. 5.8 yrs.  Would pattern of spread affect your d...

If so, what is timing after salvage radiation that you would recommend? 

Assume no evidence of regional or distant metastatic disease on imaging.

Do you use the same or more generous PTV expansions as definitive prostate cases?

Does this raise concerns about the efficacy of adjuvant immune checkpoint inhibition? Are any preliminary results from AMBASSADOR (adjuvant pembrolizu...

Weekly (20 mg/m2 D1, D2) and q 3 wks (70 mg/m2 x 3c or 100 mg/m2 x 3c) regimens have all been listed as acceptable.  For reference, RTOG 97&...

The forest plot from CheckMate 274 did not show a benefit for such patients? How would you select between adjuvant chemotherapy and adjuvant nivoluma...

For patients who are not surgical candidates and have MIBC involving a moderate to large bladder diverticulum, do you consider it safe to offer concur...

VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked. 

Would you consider boosting the nodes?  What dose?  Would this change your recommendation for length of ADT?  

Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?

Some patients will go on to develop asymptomatic intermittent hematuria which can persist... In patients with scant hematuria, what's your routine car...

Specifically, for high grade T1 bladder cancer, is there evidence that definitive radiation yields similar control rates compared to cystectomy?

NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?  What ...

Given that FCCC trial (Pollack et al., PMID 24101042) showed worse late GU toxicity with IPSS >12.

Do you think adjuvant nivolumab should be the new standard of care based on current CM274 DFS data? If OS turns out to be no different, will you still...

HCG 850, AFP normal, LDH ~500 pre-orchiectomy.  If tumor thrombus, would you favor 4c of BEP? Would you try biopsy it? How common is IVC thrombu...

How does the PSA change differ (if at all) compared to IMRT. Do you still use the Phoenix definition? What do you do if PSA is slow to decline?

How does prior chemotherapy, site of disease, and pathological staging inform your decision? How about molecular markers (PD-L1, ctDNA)?

Is a 3 month delay too long in someone who had postoperative complications?

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

Given GU003 presented at ASTRO 2021- how does this impact your recommendations for adjuvant and salvage prostate RT?

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out. 

In the case of two fractions, would you complete two fractions one week apart? Or admit after the first and do the second fraction the next day? In p...

Apart from H&N SCC, are there times where adding an extra dose of radiation due to a tx break is appropriate?  Is there a decent equatio...

Eg patient has been catching for years but now developing stenosis towards end of salvage RT course.

Given younger men have a longer period to live, are there concerns regarding long term side effects (GI, GU, secondary malignancy) between SBRT vs hyp...

Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk c...

For example, are PET Axumin or PSMA studies being ordered in the upfront setting? 

Are there any concerns with using IMRT vs 3D? 

No cord compression is present, and the patient remains symptomatic only with their upper extremity due to brachial plexopathy

MRI shows that it's not within the rectum or prostate but it does appear to be following the contour of the right peripheral zone down almost between ...

Per lutathera information, a patient who had previous treatment for describes an estimated radiation absorbed dose of 12.8 Gy to the bladder. Would yo...

For those of us just transitioning over to hypofractionation, what are reasonable, but conservative, constraints that you use?

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

How do you weigh the various efficacy endpoints in the trials of novel combinations in ccRCC?  Are there specific clinical populations that you ...

What is your approach to a patient who underwent surgery for what was thought to be a thymoma, but ended up being a pure seminoma? No disease elsewher...

Would you think differently about chemotherapy based on %teratoma or size of lymph nodes vs number of lymph nodes (eg. multiple small LN vs single 2-5...

Have you treated anyone with an implanted sacral nerve stimulator and if so, what principles did you utilize with planning? Did you modify your fields...

Or with other available IO/TKI combinations should this be strictly reserved for intermediate/high risk patients only?  If selecting IO/TKI, do ...

If any clinical benefit (ie. CR, PR or SD) would you consider switch maintenance avelumab, surveillance until progression, or an alternate regimen?

Molecular profiling revealed no targetable alterations, however tumor mutational burden was >10 mut/Mb.

Would you consider external beam radiation vs HDR vs LDR? What dose, margins, and OAR constraints would you use given prior treatment?

Do you select treatment based on toxicity profile since efficacy of regimens will likely never be directly compared? Are there QOL indices that can ...

Patient has progression of liver metastases while on pembrolzumab/axitinib. ECOG PS 1 and limited comorbidities.

Do you tend to do HDR before or after external beam? Is there more toxicity with one approach?

Would you offer external beam radiation if the prostatectomy specimen showed a high Gleason score with involved margins?

Is there a benefit to cytoreductive nephrectomy if residual metastases are not resected? Any benefit to extending surgery to other metastatic sites?

Would you be less likely to recommend in a patient? Are there any increased vascular, GI or GU risks? Any strategies you employ to mitigate risks?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 

The recommended concurrent chemotherapy regimens (cisplatin/paclitaxel and cisplatin/FU) in NCCN are based on BID fractionation of radiation as in RTO...

If the patient has received the majority of treatment, such as 24 of 28 planned fractions (60/70 Gy), and then had a 1 - 2 week unexpected break, woul...

How would non-regional adenopathy change management? What about poor surgical candidacy?

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

Is age ever a concern given the potential side effects of long term ADT? 

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

Would radical prostatectomy and PLND suffice or would a cystectomy be warranted (even in the absence of bladder involvement) as well? 

If no direct invasion into prostate from bladder or urethra, is there any role for systemic therapy?

Are there any risks to future transplantation into the pelvic area that would outweigh the benefits? 

Are there planning techniques that you can utilize to improve dose homogeneity?

For the purpose of this question, please assume an initially undetectable post-prostatectomy PSA, no presence of positive margins, extracapsular exten...

Does patient age effect your approach? Would you consider RPLND for any patients in light of the phase II SEMS trial presented at the 2021 ASCO GU Ca...

Patient underwent SBRT without recurrence and now has symptomatic internal hemorrhoids causing intermittent fecal incontinence.  His colorectal s...

Are there certain situations where a hydrogel spacer is most useful based on treatment modality (SBRT, protons, brachy, etc) or other factors?

Are there any anatomical changes that would make the placement impractical or hurtful for the patient?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

Do you have a prostate volume/size threshold? Baseline urinary function? Any other anatomy or patient factors that may make patient not suitable for...

For example, if 2 pre-biopsy PSAs are 23 and then 18, would you stratify as intermediate or high risk? If otherwise intermediate risk, would you treat...

In reviewing the data, LDH does not upstage to intermediate risk but those patients tend to do worse. Would one treat this patient as intermediate ri...

What is your preferred dose and fractionation? Do you utilize 4D simulation? Additionally, how conservative are your constraints for ipsilateral uninv...

Is DFS benefit in KN-564 in ASCO2021 sufficient evidence to change practice?

A recent study showed an improvement in bichemical failure with higher doses. How much impact do...

Assume treatment was 5 years ago and patient no longer has diverting ostomy. Would surgery or radiation be preferred given both have increased risks? ...

Assume a patient has both obstructive and incontinent symptoms. Is there anything to do about the expected and subsequent worsening of their urinary f...

Assume this is a PET Axumin avid node and is only site of disease. Previously this high risk prostate cancer patient had 45 Gy to the whole pelvis and...

Given long term data from Keynote 052 for pembrolizumab presented at ASCO 2021. What factors impact your treatment decisions? For cis-ineligible PD-...

HDR CT planned prostate brachytherapy stipulates bladder V75% Rx<1cc. What bladder constraint is used for LDR prostate brachytherapy?

Do you manage post radiotherapy onset of tensmus differently? 

Would you radiate? Surgery? Chemo? Follow with short interval scans? How would size of adenopathy (e.g. <2cm vs larger) and time of recurrence (wi...

Do you prefer to treat patients with factors such as large prostate volume, significant comorbidities, anticoagulation use, history of TURP, or high A...

Is inclusion up to the bifurcation worth the bowel dose? Or are you contouring up to the L5/S1 interspace? 

What clinicopathological features would need to be present for you to recommend adjuvant chemotherapy? Would you treat pT3 disease? Any specific histo...

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

Are there any circumstances that would necessitate treatment? 

Is there data to suggest that omission of elective nodal coverage to the pelvis similar to the omission of elective lung nodal coverage in lung cancer...

What would your treatment approach be- surgery or chemoRT? What is your preferred chemo regimen? Is there a % threshold other than 100% (e.g. 95%) th...

Do you contour to include S3 or up to the piriformis muscle?

Given publication by Spratt, et al JCO 2021, how do you sequence ADT? PMID: 33275486 JCO, 2021, Spratt D et. al, Prostate Radiotherapy With Adj...

Would you have reservations in treating patients with breast, GI, or pelvic malignancies with radiation alone or concurrent chemoradiation?

There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you u...

Is the short time to recurrence a reason to not consider definitive management with surgery/radiation? Should systemic therapy be added if pursuing d...

Specifically, for cT2N0M0 small cell bladder cancer without response to neoadjuvant cisplatin and etoposide on imaging, would you proceed with cystect...

Do you treat the pelvis or omit? Do you have more tighter constraints for rectum or bowel? 

The STAMPEDE trial recently published in Lancet used 55 Gy in 20 fractions but did not include dose constraints.

We have encountered multiple patients whose pre-ADT Testosterone was >1500 (Normal range 264-916) and sent them to Endocrinology to evaluate for so...

Given consensus contours for prostate bed, volumes can approach the sigmoid and include a significant amount of bladder, how do you meet these objecti...

For patients who have progressed on first line checkpoint inhibitor (e.g. Nivo/Ipi) and second line TKI (e.g. Cabozantinib) 

Should the prostate be rebiopsied, or would you proceed with radiation therapy given the relatively high failure rate of cryotherapy as initial treatm...

Given prognosis is poor per Oing, et al, Annals of Oncology, 2016, would you recommend radiation?

What systemic therapy options are available for ESRD patients?

It seems that patients have an easier time maintaining a full bladder at the beginning of treatment compared to end of treatment. 

NRG GU-006 included the following as part of its eligibility criteria: “Persistent elevation of PSA after prostatectomy measured within 90 days ...

Would you consider 55 Gy in 20 fx to the primary followed by SBRT to oligo sites? Would you consider concurrent immunotherapy? Or would you just proce...

Assume treating to 64-66 Gy.  Do you simulate bladder cancer patients with full and/or empty bladder? Do you ever add your own delayed IV contr...

Do you perform a DRE at consultation and/or in follow up?  Do you feel that performing a DRE changes your management?

What clinical scenario(s) do you find results to be the most beneficial?

Is there a role for neoadjuvant cisplatin-based chemotherapy? Do patients with sarcomatoid histology respond to checkpoint inhibitors?

Are they necessary? Any group of patients that you use them on (concurrent ADT, anemia, or use of whole pelvis, etc)?

Patient had had multiple surgeries and non healing wounds. If so, what dose/fractionation did you use?  Did your patient have durable control of ...

If so, how would you design and deliver the treatment?

Would you offer SBRT?  What criteria do you use to consider SBRT?  What dose limits do you place on the glenohumeral joint?

There are so many available options—standard fractionated RT, moderate hypofractionation, SBRT, protons, combined EBRT and brachy—how do y...

Does PSMA have enough data to use to guide therapy, even if the result is obtained as part of a clinical trial? Would you change your hormonal recomme...

No actionable mutation on NGS testing. What approved therapy do you prefer? Are there specific investigational agents currently in clinical trial...

What would you consider if the recurrence occurs multiple times in the prostate? Salvage surgery if a candidate?  HIFU or cryo?  ADT?

What makes you favor ADT vs local therapy? Any preferred local therapy options? Any other special considerations?

Prospective single arm studies with short term follow-up were recently presented in abstract form (Kishan et al, IJROBP, Oct 2017; Mallick et al, IJRO...

If no testicular mass on exam or ultrasound - is there a role for orchiectomy? What chemotherapy regimen would you use and how many cycles?

Patients can have this for many reasons including being completely anuric, incontinence, nephrostomy tubes, etc.

If you would offer radiation, what dose do you recommend? How do you simulate and treat the patient? The patient is not a surgical or chemo candidate.

Assume PSA less than 0.5. Would axumin positive nodes change your mind? What dose do you use? Do you require biopsy first to prove pathologic nod...

For example, is there any data to suggest a benefit to starting with immunotherapy prior to TKI or the alternative?

Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

Is a detectable PSA on ADT a harbinger of biochemical recurrence? Is there a threshold value above which you are concerned (ie. 1.0 vs  0.5 Ng/mL...

If you recommend adjuvant radiation, how would you treat this? Because of the cystectomy, there is no typical prostatic fossa.

The recently published executive summary from ASTRO/ASCO/AUA hypofractionated radiation therapy for localized prostate cancer states "Five-fracti...

Is there any specific precautions or concerns to consider with TKI initiation if the patient has vasogenic edema?

RTOG 0815 protocol says 1 cm from base of SV in any direction. Some contour the SV visible in the slices within 1 cm sup/inf from base of SV.  P...

(assuming that the patient is int-poor risk, has measurable disease outside of the CNS, warrants treatment with appropriate PS)

In a patient who has undergone prior cryoablation for prostate cancer and develops a biopsy proven local recurrence, what dose and fractionation would...

Given CHAARTED and STAMPEDE, what would you recommend? Would lymph node vs osseous mets change your recommendation given the trial did allow patients ...

How reliable is MRI only diagnosis of prostatitis? Assume no prior PSA and Group grade 2 or 3. Would you treat prostatitis? How do you deal with ADT e...

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

Given the length of the scan and higher likelihood of patients being unable to hold their bladder, do you deviate from CT simulation and treatment ins...

Do you prefer surgery vs radiation? For surgical patients, do you offer neoadjuvant chemotherapy? If so what regimen? 

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

Is there data and FDA approval for this indication? What about for nodal failure after radiation? 

Based on recent data published suggesting an OS advantage to the addition of ADT vs. brachytherapy boost to EBRT (Jackson et al, 2020), it is unclear ...

In the HERO trial, relugolix, a highly selective oral GnRH antagonist, demonstrated faster and sustained castration, faster testosterone recovery, and...

Do you ever recommend TURP, short course of ADT or other treatments prior to RT to downsize?

An ASCO 2020 poster from the German Testicular Cancer Study Group found that 37% of CSIS seminoma and nonseminoma were miscatagorized resulting in ina...

What dose constraint would you use for the neobladder? Small bowel constraint of 54Gy? Or would you recommend observation or ADT alone or low dose RT ...

Should treatment be based on current histology (rhabdomyosarcoma) or origin (germ cell)?

Any comments/recommendations regarding the UK approach using 52.5Gy in 20 fractions (Chin et al., IJROBP, 2020)?

Is there a contraindication to radiation therapy for prostate cancer in patients who are carriers of ATM mutation? Would you offer surgery upfront? Hy...

Would you recommend conventional fractionation or moderate hypofractionation over SBRT or brachytherapy?

Would you consider this even though this falls out of scope of STAMPEDE trial? Under what circumstances would you consider such an approach versus not...

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

Is there data that hilar location is a contraindication? Any increased risk of ureteral stricture or other unforeseen issues? What dose/fractionation ...

How does recommendation change if this a favorable intermediate, unfavorable intermediate or high risk patient? Is additional imaging or biopsy recomm...

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?

U of Alabama paper states no max dose constraints used but they try to keep V60 < 10% or 10 cc (these constraints appear to be difficult to achieve...

Would you consider SBRT and if so what dose/fractionation would you use if the lesion was in the head of the mandibula? If not would you give a fract...

Is a positive imaging enough to confirm the diagnosis? If not, what situations are appropriate for a biopsy?

How would a much higher risk cancer affect decision making? How would you treat him? 

If a patient has had a diagnostic MRI, can you obtain another planning MRI after fiducial marker and SpaceOAR placement? 

Concurrent? Neoadjuvant and concurrent? If neoadjuvant, how long before? 

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging.  Are you utilizing these speciali...

Would you be more mindful of bladder dose or hotspots? Are urinary outcomes different if the surgical procedures are done before or after radiation?&n...

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

Patient had multiple positive margins and is on ADT.  What would your treatment volumes be and to what dose?

Do you recommend before and/or after procedures? Do you have the same recommendations for any or all the below: hydrogel space, fiducial placement, LD...

Given the publication by Malone, et al (JCO, 2019), how do you sequence ADT relative to the start of RT?

Do you routinely include pelvic lymph nodes, prostatic urethra, and prostate?

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

Patient had neoadjuvant ADT. Are there any preferred isotopes, seed activities, etc for small prostate brachytherapy?

Any difference if patient is undergoing HDR vs LDR? For example, prescription doses are 45Gy for EBRT and 10.5Gy x 2 for HDR boost. 

Would you recommend radiation to the prostatic fossa and/or the oligometastatic site? How would you dose these areas? Would you recommend ADT?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

NCCN include active surveillance as an option in specific circumstances based on Rini et al. (Lancet Oncology 2016) however this set is not well defin...

Would you treat with chemoimmunotherapy based on IMvigor130 data presented at ESMO Congress 2019?

e.g. lymph node metastasis, presence of tumor involving the peritoneal surfaces and/or the abdominal wall. If so, which regimen would you offer?

The patient's urologist will not offer testosterone supplementation unless he undergoes definitive therapy of his early stage prostate cancer. Are the...

Wouldn't lymph node dissection improve sensitivity of staging and inform adjuvant treatment decisions?

Based on the RADICALS-RT trial presented at ESMO, can RT be omitted in post op prostate patients in favor of salvage RT? If not which group of patient...

i.e. gross disease on scans that is too diffuse to be removed completely and/or decreasing but not normal markers Do you pursue close surveillance, s...

If there was still was PSMA PET/CT activity in the prostate after a year of ADT would you offer RT to the prostate +/-nodes? 

Does time interval from initial radiation therapy matter. Assume this is in the case of castrate resistant prostate cancer in which all other avenues ...

Will your recommendation change if there is suspicious/confirmed locally recurrent nodule in the prostate bed?

Specifically, would you consider utilizing sodium thiosulfate in adults based on the pediatric data from Brock et al. NEJM 2018?

68 y.o. Male underwent inguinal orchiectomy and spermatic cord resection of a 5 cm malignant fibrous histiocytoma of the spermatic cord. Margins of re...

How do you assess risk of tumor lysis syndrome, and is hydration sufficient or should hypouricemic agents be used as well?

What would be a safe dose for ifosfamide and how would you time with HD? Alternatively, would you recommend a different regimen? What about using neoa...

Would you require the rituxan to be held prior to radiation?  Would this matter if it was in the post-prostatectomy setting?

UpToDate indicates that VIP is an alternative to BEP for men who are not candidates for bleomycin, and that one criteria for not being such a candidat...

Patient has small cell carcinoma of the bladder with extensive hepatic metastases. Would you extrapolate the approach from IMpower133?

Should cystectomy remain standard of care? (Recently debated in JAMA Oncology:

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

If a patient had biopsy proven gleason 6 disease 3-5 years ago and has had a slowly rising PSA to between 15-20 over the past year or 2, would you req...

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

Would you give chemotherapy concurrently with radiation? Would you change your radiation dose?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

Would you offer definitive management with radiation and ADT? Or systemic therapy alone such as with ADT+abiraterone?

Do you prescribe antiandrogen beyond the typical 2-3 weeks after starting LHRH agonist therapy to prevent testosterone flare? If so, for how long do y...

ENZAMET and TITAN trials published at ASCO 2019 show benefit to both 2nd generation AR antagonists when compared to placebo but wondering how this wil...

For example in a patient with a good performance status and a biologically favorable cancer (ER+ breast cancer, EGFR+ NSCLC, or prostate cancer), are ...

Is there any role for definitive prostate radiation extrapolating from the Stampede and recent RTOG 0521?

Would you consider scrotum contaminated and consider including it in fields?

Would you administer extended field radiation therapy?  Would you omit radiation therapy?

Does the update of RTOG 96-01, presented at ASTRO 2015, change your practice for these patients? Or should ADT be limited to a particular subgroup?

Are there any patient and/or pathologic features that would lend you to considering IL-2 over other approved I/O or TKI therapies?

How does it vary by technique (standard fractionation, hypofractionation, or SBRT)? Does your PTV change if you are treating pelvic lymph nodes?

For example, if the patient has low PSA, Gleason 6 disease but has high volume (>50% positive cores) would that discourage you from recommending ac...

Arterial events have clear instructions to permanently discontinue on the FDA label.  Especially in HCC without many other treatment options, giv...

Do you prefer LDR prostate brachytherapy first or as a "boost" following external beam radiation therapy?

Is there a benefit to one fractionation schedule v. the other?

Is there a strong rationale for treating the whole prostate (not prostatic urethra) electively to 41-50 Gy?

Would you consider EBRT alone, brachytherapy alone, or EBRT with a brachy boost? Would you counsel these patients differently regarding short/long ter...

If the patient had pelvic adenopathy, would you include that in your treatment volumes?  What dose and fractionation would be considered appropri...

The original study used 50% of positive cores, but the MSKCC nomogram can give a high risk of EPE with just 4-5 positive cores out of 12

Given that it is cleared from the body by renal filtration, are you concerned about clearance issues?

For example, in standard high-risk we generally cover proximal 2cm to elective dose, before doing cone down boost to prostate and proximal 1cm. If a ...

In particular would it affect the decisions for brachytherapy or androgen deprivation? How do you monitor for treatment response since they may not m...

Are there problems with volume changes from the spacer dissolving while the patient is on treatment? What is your department's protocol for these type...

In light of the data from ERA223 showing increased deaths and fractures with the combination of radium-223 and abiraterone compared to abiraterone alo...

Assuming no advanced imaging is available, what lymph node morphologic criteria (ie. lack of fatty hilum, size, number of nodes, etc.) do you use to u...

If a patient's PSA goes from undetectable to minimally detectable (ie 0.03-.05) would you wait to offer salvage radiation?  Would your recommenda...

Which risk estimator is felt to be the most accurate and what threshold? What's the best contouring guidelines for ENI for prostate?

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

If the patient is in remission for metastatic melanoma but continue to take an anit-PD1 therapy, it giving ADT, EBRT + brachytherapy safe for a high r...

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

For example, do you change your prescription dose, treatment schedule, or OAR constraints? Have you noticed increased toxicity in older patients, e.g....

For example, for the first 25 fractions, you would treat the rest of the pelvis in 1.8 Gy/fx to 45 Gy, and then using a SIB treat the prostate/proxima...

What factors would you consider? What if this meant treatment of the full kidney? If treatment is recommended, would you utilize an SBRT approach...

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

Node-positive patients were not eligible for ASCENDE-RT, and the current NCCN guidelines do not list brachy boost as an option for regional ...

What is the upper limit of size you would consider offering a patient a five fraction regimen?

If so, what dose? What if there is positive a PA lymph node but no signs of distal mets? 

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

If so, would you offer pelvic lymph node irradiation in these patients if they have pathologically node positive disease?

Do you change your treatment volumes, particularly when treating the seminal vesicles, to avoid the ureters?

Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?

Do you use a specific threshold number of sites to make your decision? Apart from assessing for cytopenias, do you consider any other patient factors?

In a patient s/p orchiectomy and with pelvic lymphadenopathy, would you consider lymph node biopsy to confirm involvement by non-seminomatous germ cel...

Would you treat this patient any differently than any other very high risk prostate cancer patient?  Are there any additional dose constraints fo...

Most of the studies have excluded non clear cell histologies. If you use a similar approach to clear cell, have you seen similar responses?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

The recent SPARTAN trial showed a remarkable improvement in metastasis free survival and many other secondary endpoints except the lack of significant...

Do you maximize rectal emptiness at the time of sim (ex with enema if needed) or do you simulate with a full rectum since this is most reproducible?&n...

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

Specifically, would the addition of a brachytherapy boost impact his ability to receive future intravesical therapy?

What are the special considerations in the non-metastatic setting vs metastatic setting?

If the patient is refusing hormone therapy is there a contraindication to prostate RT with concurrent 5FU-based chemotherapy?

Many patients are still able to orgasm but are disturbed by the loss of seminal fluid.

Testicular ultrasound, CT, and tumor markers are without abnormalities outside of the mass.

There are now five PD-1/PDL-1 inhibitors approved for metastatic bladder CA, one (Atezolizumab) as first-line therapy in cisplatin-ineligible patients...

Is MRI fusion is adequate for urethral delineation and sparing?  Would you worry about prostate deformation by placement and removal of catheter ...

Specifically, does the Decipher score influence the incorporation and/or duration of ADT? Can it be used to better stratify intermediate risk patients...

Specifically, in patients who have an undetectable PSA post-op, with high risk features such as seminal vesicle invasion, positive margins, or extrapr...

Using the standard whole bladder dose fractionation used in BC2001, 55 Gy in 2.75 Gy fractions.

For instance: urologists who only refer for a rising PSA, even in a patient with high-risk features, those who use Decipher results to decide when to ...

What systemic therapy do you use? Do you incorporate any multi-modality therapies?

Based on the updated results of the PCS IV trial is 18 months of ADT the new standard of care for men with high-risk prostate cancer treated with...

Is there any information on how ADT affects the test operating characteristics?  

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

Does histology, i.e. urothelial carcinoma versus squamous cell carcinoma, impact this decision?

Are there any other medications, outside of anticoagulation, that would be considered absolute or relative contraindications?

Is a single-fraction HDR boost appropriate following conventionally fractionated EBRT to 45-50.4Gy?

Pt previously treated with radical prostatectomy and adjuvant radiotherapy. If recommending therapy, what is the role of concurrent abiraterone + AD...

What dose would you use?  Would your approach to elective nodal radiation be different in the preoperative setting?

Based on new FDA approval of nivolumab plus ipilimumab in the first-line setting for intermediate- and poor-risk disease, would you give the combinati...

Could observation and serial cystoscopy be a reasonable option or is surgery necessary? If recommending surgery, can a procedure less than a nephroure...

If the two intermediate risk factors are on the lower end of intermediate risk (ex GS 3+4 and PSA 11) with a very small volume disease, can a more int...

Is it better to treat without hormone suppression?  Or would this be reason enough to push the patient toward prostatectomy?

Data reported by Motzer et al Lancet 2015 demonstrated a statistically superior PFS benefit of lenvatinib monotherapy over everolimus alone. In partic...

Assuming you are treating whole bladder only with concurrent chemotherapy, when would you recommend hypofractionated radiation (20 fractions) vs stand...

In the case of patients many years out from RP who have a slowly rising PSA, do you offer salvage RT while the PSA is still very low or follow the PSA...

Recent evidence has been mixed, with no DFS or OS benefit in 1 trial (ASSURE, Haas et al, Lancet 2016) and DFS benefit in another (S-TRAC, Ravaud et a...

If Dynamic Sentinel Lymph Node biopsy is not available, would you refer the patient for node dissection, radiate, or observe? What nodal regions would...

In a patient who has a rising PSA, palpable nodule, MRI findings etc., is it ethical to treat the patient with inadequate information and ri...

For example, previous RT for seminoma several decades ago. How about a more recently treated rectal cancer with pre-op chemoradiation?

Given the apparently stronger results from KEYNOTE 052 (pembrolizumab) compared to IMvigor 211 (atezolizumab), would you consider pembrolizumab for pa...

How do you prioritize alignment of bony anatomy, prostate and nodes? Do you have varying PTV margins for different structures or as compared to prost...

ASCENDE-RT excluded these patients as well as those with a PSA > 40, but it seems these patients may stand to benefit as well.

Does the 1 year of ADT used in the ASCENDE-RT trial present a new option of the standard of care in timing ADT when combined with brachtherapy boost?

The current treatment for bladder adenoCA is surgery. However in non-surgical candidates, RT is an option. Would you consider adding chemo ? Also woul...

Our urologists routinely get these scans prior to definitive therapy and at times in the postprostatectomy setting.  The high sensitivity makes f...

Specifically, what criteria do you use to quantify "low-volume" prostate cancer?  What other criteria do you consider when defining low volume in...

If so, what chemotherapy regimen would you use? If not, what management options would you generally recommend?

Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earli...

cT3 patients were a minority of patients in the data demonstrating superiority of tri-modality therapy. While cT3b patients have particularly poor out...

If current systemic treatment is otherwise controlling the disease and is well-tolerated, is there value to locally aggressive therapy in an attempt t...

Can radium-223 be given to patients with progressive diffuse osseous mets if they have a history of visceral mets that resolved with previous treatmen...

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

Are the results of the STAMPEDE trial presented at ASCO 2017 practice changing?

Is there a length of time that would be considered too long between TURBT and CRT? At what time point would you recommend another cystoscopy to evalua...

Do you use the same constraints that you would for the rectum? Or perhaps employ a lower dose limit, such as not exceeding 65Gy to a small volume of t...

With biopsy-proven, negative systemic restaging disease, what dose and fractionation is appropriate if treating with IMRT? Should ADT generally b...

Given the non-specific nature of AFP and its elevation in various benign conditions, is there an AFP cutoff level or change over time for which you wo...

Would you offer it for positive margins? NCCN says to consider adjuvant radiation for pT3-T4 or pN0-2. Is there sufficient evidence for adjuvant radia...

Which patients do you consider to be chemotherapy-ineligible for the sake of this treatment decision? How strong does the contraindication need to be?

Would you consider this an indication to treat lymph nodes, if you would typically not do so?

What clinical considerations factor into your decision to choose leuprolide vs goserelin vs triptorelin vs degarelix, etc?

NCCN guidelines offer suggested schedules for interval imaging and laboratory studies, but also make it clear that the quality of evidence for these r...

Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?

What determines which you select first? How do concerns about cross-resistance factor in after progression on one of these agents?

To what extent do you worry about overlapping myelosuppression? Is there any advantage to overlapping therapy?

Standard RTOG constraints include guidelines for rectal v60, v65, v70, v75, but is there a relative or absolute volume constraint for rectal v80 that ...

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

Should the workup change with the PSA level (for example, >2 vs <2 ng/ml post-op PSA)?  Is there a PSA level for which salvage radiotherapy...

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

Are patients with extracapsular extension at diagnosis good candidates for brachytherapy boost? If extracapsular disease that can't be effectively&nbs...

How do you minimize these risks? If using local anesthesia only in the outpatient setting, how is pain control at the area of injection?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

And how should we compare checkpoint inhibitors? Given the FDA approval of atezolizumab and nivolumab as second-line agents for metastatic urothe...

Is there any benefit to delaying start of RT or perhaps changing to complete adrogen blockage if maximal PSA response is not achieved in 2 mo?   ...

If so, when? There seems to be an increasing trend among urologists to offer surgery to high-risk prostate cancer patients despite the low probability...

Are fiducials always necessary? Does your answer differ if you're treating with standard vs. moderate vs. extreme hypofractionation?

We are being referred more patients for salvage radiation after this procedure, not sure what the evidence is.

Specifically if sentinel node mapping and sampling has not been performed or refused?

When would you use surveillance versus repeat excision or adjuvant systemic or local therapy?

Do you have a cut off in terms of prostate size, IPSS score,  post-residual void volume, or any other criteria?

If so, is there a role for IMRT?  I was taught to use the RTOG style ports with whole pelvis 4 field box and then boost field to entire bladder ...

The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib. 

In the recent 10 year update of the ARO (adjuvant pelvic RT versus observation) trial, their definition of PSA failure was 2 successive rise...

In the setting of recent craniotomy and a plan for SRS to the surgical cavity, which systemic therapy would you choose and when would you start it?

How would you manage the small bowel/prostatic interface? Have you tried SpaceOAR in this context? SpaceOAR + protons? What dose would you escalate to...

For a patient with a history of non-muscle invasive disease in the bladder, presenting with a prostatic urethra only recurrence, do you approach this ...

When do you offer trimodality bladder-sparing approaches? Is there any role for starting standard neoadjuvant therapy in an attempt to convert to rese...

Or in patients with metastatic disease on ADT who have not had primary therapy? In what situations do you consider palliative prostatectomy?

After confirming castration levels of testosterone, is the next best step to add docetaxel (as in CHAARTED and STAMPEDE, although not explicitly for G...

When are you concerned for a false positive? FDA guidelines include a suggestion to try another assay in case heterophile antibodies are causing a fal...

Is it true that urinary obstruction can improve with HDR brachy, as it can have an ablative effect on the prostate?

Radium-223 has an overall survival benefit and lower hematologic toxicity, but at a significantly increased cost.  Does the cost-effectiveness fa...

If so, at what point? McDermott et al. demonstrated some lasting responses after discontinuation of therapy (JCO 2015), but these responses are s...

Would a minor adverse pathologic features such as capsular penetration (not SV or positive margins) influence the decision for radiation treatment? W...

How might a recent (within 6 months) myocardial infarction affect your recommendations?

For patients who developed oligometastases while off systemic treatment, do you start systemic therapy following local therapy or return to active sur...

Are there circumstances when you would choose IL-2 over checkpoint inhibitor trials or TKIs for fit patients? How should IL-2 be sequenced with these ...

In which circumstances should high-dose chemotherapy with autologous stem cell transplant be considered, versus second-line chemotherapy regimens or c...

Based on the abstract from IMvigor 210 presented at ASCO this year, are you offering atezo to patients who otherwise may not tolerate platinum-based c...

Based on a recent single-arm phase II trial, is there a role for paclitaxel, ifosfamide, and cisplatin (TIP) as a first-line regimen instead of BEP?

There is limited data to guide us in this relatively uncommon situation (PMID 7853587, PMID 2836634). Would this presentation...

The mid treatment cystoscopy has been standard, but treating with or without mid-RT cystoscopy are both included in the NCCN guidelines. Can the treat...

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

The forrest plot in the recent meta-analysis published in European Urology is rather impressive, even in the more recent high dose radiation series.&n...

For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in thi...

Does PSADT play a factor in your decision-making? If so, how specifically?  I've tended to wait until the PSA is 10-15, re-image, and then begin...

Should it be routinely used for all patients? Or should it be used for specific risk groups such as unfavorable intermediate risk patients to rule out...

If so, how do you sequence this with other therapies?  In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

In the IMvigor 210 trial, increased PD-L1 expression in patients’ tumors was associated with response to atezolizumab, but some patients whose t...

Given the excellent results from the ASCENDE-RT trial, should we be combining EBRT and brachytherapy? What criteria do you use to determine when ...

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

If a patient has only IR disease factors but "findings suspicious of extraprostatic extension" on biopsy or MRI or both, would this upstage the patien...

Since the benefit of neoadjuvant chemotherapy is well-defined in muscle-invasive bladder cancer, is it reasonable to consider this in upper-tract tumo...

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521.  Following prostatectomy,...

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

There are a wide range of seemingly safe/effective regimens in the published literature, with an associated array of BED/EQDs and little more to guide...

 In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies.  Is there a population of men w...

Recently, Epstein et al proposed using a Grade Group system of Groups 1 (GS < 6), 2 (GS 3+4=7), 3 (GS 4+3=7), 4 (GS 4+4=8), and 5 (GS 9-10). T...

In this trial, 6 months of concurrent LHRH agonist therapy improved 5-year progression-free survival from 62% to 80%, with similar benefit in low-risk...

What can be done prior to RT to prevent this? (Flomax/hormones not helping)

Do you treat to full dose or a lower dose with a cone down to the prostate PTV? Is there any data to support a particular dose?

For a recurrence after nephrectomy, the NCCN recommends surgery or, in inoperable patients, systemic therapy. There is no mention of SBRT in...

In a man with castrate resistant disease invading into the bladder and rectum, I have been told that 30Gy/10 fractions to the prostate is inadequate, ...

Guidelines dont seem to account for this possibility. Could it just be normal prostate tissue growing back that is leading to PSA, why just assume it ...

What number of cores and what % cores involved do you look at to consider them low-intermediate risk for prostate SBRT?

In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?

Although the landmark randomized trials treated up to 64 Gy, there is data out of Italy suggesting that higher doses yield better biochemical control ...

On what other factors should be considered in making a treatment recommendation for salvage radiation therapy?

Do you favor a short palliative regimen, or a full course definitive treatment to 64.8Gy? How does your management change if the patient has a good pe...

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

With ultra-sensitive PSA, it's unclear to me whether a doubling from 0.01 to 0.02 or 0.02 to 0.04 is significant. Is there a certain value that you wo...

If a patient is deemed high risk enough to require hormones with RT in the salvage setting, how long would you maintain them on ADT? Would you extrapo...

When counseling patients with organ-confined prostate cancer, what rates of impotence, incontinence, rectal toxicity, and urethral stricture shou...

Would a history of prior vasectomy in a stage IIA seminoma be an indication to include the inguinal nodes in the RT treatment field?

Is there any advantage to primary RT as opposed to just orchiectomy? Additionally, in order to confirm Tis, a biopsy is required, which is typica...

The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, g...

I've heard justification for treating the whole bladder to 60-64 Gy based on the UK MRC study (James et al. NEJM 2012 and Huddart et al. IJROBP 2013) ...

Realistically, there will always be some (hopefully small) inconsistency with bladder filling, and thus some small bowel could easily receive &ge...

Assuming a patient who could tolerate either, which is preferred? Does this depend on the choice for concurrent chemotherapy (5FU+mitomycin vs ci...

The Chung validation study did not find that size > 4cm or rete testis invasion are risk factors for relapse and the current NCCN guideline discour...

Do you use a particular cut-off? For example, someone in their 40's?

The patient has a positive bone scan (2 lesions), grade 4+5=9/10 prostate, and cancer cannot urinate without a catheter.

In the definitive setting, and would that change if cystecomy was planned if there was a complete response after CRT?  (similar to TCC paradigm).

Eight years after brachytherapy for a low risk prostate cancer, a patient has unresectable high grade squamous cell carcinoma of the bladder. Should I...

More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?

In general how do you counsel patients with high risk prostate cancer when choosing radiation verse prostatectomy? What numbers do you quote for ...

This is a patient who would have been an appropriate candidate for radiation upfront, but was managed with androgen deprivation therapy instead. On th...

Sometimes the scans don’t line up well because of differences in rectal and bladder fullness- any tips to optimize the fusion?

I ask this because I am seeing more and more patients who have had surgery despite presenting with high risk disease.

I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage?

And should special precautions be taken (such as dose reduction, prophylactic symptom management, etc)?

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2005-04-01

Int J Radiat Oncol Biol Phys, 2005 Sep 1

International journal of radiation oncology, biology, physics, 2004-06-01

International journal of radiation oncology, biology, physics, 2007-08-01

International journal of radiation oncology, biology, physics, 2014-04-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Int. J. Radiat. Oncol. Biol. Phys., 2012-12-01

European urology, 2013-12

CA Cancer J Clin, 2010 May-Jun

J Natl Cancer Inst, 2010 Jan 6

BJU international, 2014-12

JAMA, 2011-12-07

Cancer, 2013 May 15

International journal of radiation oncology, biology, physics, 2010-11-01

American journal of clinical oncology, 2016-02

Radiother Oncol, 2013-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-20

Eur. Urol., 2009-05-01

The American journal of surgical pathology, 2005-09

The New England journal of medicine, 2012-07-19

BMJ, 2014-01-08

International journal of radiation oncology, biology, physics, 2012-05-01

International journal of radiation oncology, biology, physics, 2012-02-01

Nature clinical practice. Oncology, 2005-05

Practical radiation oncology, 2012

Urology, 1999-10

Urology, 2001-04

Int J Colorectal Dis, 2012-11-01

N. Engl. J. Med., 2009-06-11

JAMA, 2006-11-15

Practical radiation oncology, 2013

N Engl J Med, 2008 Mar 20

The Journal of urology, 2011-09

Practical radiation oncology, 2013

N. Engl. J. Med., 2012-04-19

Practical radiation oncology, 2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

The Lancet. Oncology, 2006-06

European urology, 2011-05

International journal of radiation oncology, biology, physics, 2014-04-01

Lancet, 2008 Dec 16

Lancet, 2011-12-17

Journal of the National Cancer Institute, 2015-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Urologic oncology, 2014-04

BJU international, 2014-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

J. Urol., 1998-01-01

Eur. Urol., 2014-03-01

BJU international, 2015-10

The New England journal of medicine, 2011-07-14

International journal of radiation oncology, biology, physics, 2010-04

JAMA, 2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

The Journal of urology, 2012-01

Int. J. Radiat. Oncol. Biol. Phys., 2012-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-07-01

Int. J. Radiat. Oncol. Biol. Phys., 2004-05-01

Cancers, 2022 Jan 29

International journal of radiation oncology, biology, physics, 2013-03-15

Cancer, 2014-06-15

Cancer, 2006 Jun 15

International journal of radiation oncology, biology, physics, 2003-03-15

Urology, 2008-11

International journal of radiation oncology, biology, physics, 1990-09

Radiother Oncol, 2006 Oct

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

American journal of clinical oncology, 2014-06

International journal of radiation oncology, biology, physics, 2011-07-15

International journal of radiation oncology, biology, physics, 2010-07-15

Frontiers in oncology, 2011

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-20

The New England journal of medicine, 2017-02-02

JAMA Oncol, 2017-10-01

Seminars in radiation oncology, 2013-07

Eur Urol, 2015 Jul 16

BJU Int, 2009 Feb

European urology, 2014-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-20

Lancet, 2012-03-24

The Journal of urology, 2013-08

The New England journal of medicine, 2013-07-18

Lancet Oncol., 2016-06-01

Transl Androl Urol, 2016-12-01

Int. J. Radiat. Oncol. Biol. Phys.,

BJU Int., 2012 Jul 03

Int J Radiat Oncol Biol Phys, 2012 Jul 15

Urology, 2016-04

JAMA Oncol, 2020 Aug 27

Lancet, 2016 Mar 19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

International journal of radiation oncology, biology, physics, 2012-04-01

Eur. Urol., 2006-10-01

European urology, 2011-04

Urology, 2001-11

Clin Oncol (R Coll Radiol), 2015-01-01

Radiother Oncol, 2015-06-01

The New England journal of medicine, 2015-08-20

Int. J. Radiat. Oncol. Biol. Phys., 2012-03-15

Prostate, 2014-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-11-01

International journal of radiation oncology, biology, physics, 2001-08-01

International journal of radiation oncology, biology, physics, 2002-11-01

International journal of radiation oncology, biology, physics, 2015-06-01

N. Engl. J. Med., 2017-07-27

International journal of radiation oncology, biology, physics, 2015-11-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Urologic oncology, 2016-09

The Journal of urology, 2009-03

N. Engl. J. Med., 1999-12-09

Lancet, 2012-12-08

Eur. Urol., 2014-08-01

The New England journal of medicine, 2004-10-07

J. Clin. Oncol., 2016-05-20

BJU international, 2014-09

Radiother Oncol, 2016 Jun 04

BJU Int, 2012 Feb

European urology, 2017-05

International journal of radiation oncology, biology, physics, 2015-12-01

Eur Urol, 2016 Jul

BJU Int., 2016-08-01

J. Urol., 2005-06-01

JAMA oncology, 2016-11-01

J. Nucl. Med., 2015 Jun 25

Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 23

Brachytherapy, 2020 Apr 21

Int. J. Radiat. Oncol. Biol. Phys., 2020 Jan 24

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Lancet Oncol., 2010-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

The Journal of urology, 2005-08

Mol Clin Oncol, 2015 May 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

The Journal of urology, 1999-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

Mayo Clin Proc, 2004 Oct

JNCI Cancer Spectr, 2019 Oct 21

N Engl J Med, 1994 Aug 11

The New England journal of medicine, 2018-05-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

The Journal of urology, 2002-09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Nature, 2005-12-08

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

The New England journal of medicine, 2001-12-06

Lancet, 2001-09-22

Breast Cancer Res. Treat., 2010-02-01

The Journal of urology, 1982-06

Cancer research, 2000-04-15

J. Clin. Oncol., 2009-04-01

Oncol. Rep., 2015-12-01

Nat Commun, 2015-04-01

PLoS ONE, 2016-01-01

J. Urol., 2002-04-01

Lancet Oncol., 2015 Sep 09

European urology, 2018-02

Lancet, 2018 Oct 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

International journal of radiation oncology, biology, physics, 2012-09-01

J Clin Oncol, 2015 Dec 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

Lancet Oncol, 2016 Aug

JAMA, 2008-06-18

International journal of radiation oncology, biology, physics, 2007-11-01

N. Engl. J. Med., 2016-10-13

Health Technol Assess,

Indian J Urol,

Lancet (London, England), 2016-05-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

JAMA oncology, 2016-04

JAMA oncology, 2017-01-01

JAMA, 2009-08-26

European urology, 2015-05

JAMA, 2008-01-23

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-02-01

Journal for immunotherapy of cancer, 2015

Cancer immunology, immunotherapy : CII, 2016-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995-03

The cancer journal from Scientific American, 2000-02

Cancer immunology, immunotherapy : CII, 2016-12

Urologic oncology, 2015-11

Lancet (London, England), 2016-05-14

The New England journal of medicine, 2016-12-08

JAMA oncology, 2017-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

The Journal of urology, 2001-11

Urologic oncology, 1995

Brachytherapy, 2016

International journal of radiation oncology, biology, physics, 2013-06-01

Brachytherapy, 2014

Radiat Oncol, 2017-06-09

Canadian Agency for Drugs and Technologies in Health, 2016-10-31

Medicine (Baltimore),

Future Oncol, 2015 Oct 05

International journal of radiation oncology, biology, physics, 2006-02-01

J Clin Oncol, 2020 Mar 02

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Int J Radiat Oncol Biol Phys, 2009 Oct 14

JCO Precision Oncology, 2017 May 31

The New England journal of medicine, 2016-08-04

NEJM Evidence, 2022 Jun 3

Prostate cancer and prostatic diseases, 2014-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012-05

International journal of radiation oncology, biology, physics, 2017-03-15

J. Clin. Oncol., 2017-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

The New England journal of medicine, 2017-03-16

BMJ, 2016 Mar 2

European urology, 2016-07

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-04

International journal of radiation oncology, biology, physics, 2006-06-01

The New England journal of medicine, 2018-04-12

The New England journal of medicine, 2018-06-28

Front Oncol, 2020 May 05

European urology, 2012-04

European urology, 2014-07

J. Urol., 2007-09-01

J. Clin. Oncol., 2006-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-07-10

International journal of radiation oncology, biology, physics, 2011-06-01

Urology, 2017-04

International journal of radiation oncology, biology, physics, 2013-03-01

International journal of radiation oncology, biology, physics, 1998-06-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015-10

Future oncology (London, England), 2016-03

Future oncology (London, England), 2016-03

BJU Int., 2017-11-01

Radiother Oncol, 2016-03-01

Cancer, 2018-03-01

Eur Urol Oncol, 2020 May 22

Int J Radiat Oncol Biol Phys, 1986 Mar

Lancet (London, England), 2017-01-07

J. Clin. Oncol., 2018-06-10

Bladder cancer (Amsterdam, Netherlands), 2017-01-27

International journal of radiation oncology, biology, physics, 2016-09-01

International journal of radiation oncology, biology, physics, 2016-04-01

International journal of radiation oncology, biology, physics, 2017-03-15

International journal of radiation oncology, biology, physics, 2013-02-01

Cancer, 2014-04-15

J Clin Oncol, 2011 Jun 1

Med Dosim, 2015 Winter

International journal of radiation oncology, biology, physics, 2016-06-01

World J Urol, 2015-11-01

Int. J. Radiat. Oncol. Biol. Phys., 2014-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01

International journal of radiation oncology, biology, physics, 2005-12-01

International journal of radiation oncology, biology, physics, 2012-07-01

Oncology, 2016-01-01

Oncology, 2013-01-01

PLoS ONE, 2015-01-01

International journal of radiation oncology, biology, physics, 2012-01-01

Radiation oncology (London, England), 2016-01-21

Ann. Oncol., 2018 Feb 26

Urologe A,

J Clin Oncol, 1998 Nov

Nature medicine, 2017-06

Oncotarget, 2016-08-16

Clin Oncol (R Coll Radiol), 2016-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

JAMA Oncol,

J Urol,

Urology, 1999-06

Biomed Res Int, 2014 Feb 06

International journal of radiation oncology, biology, physics, 2011-02-01

Radiation oncology (London, England), 2014-11-15

International journal of radiation oncology, biology, physics, 2017-03-15

International journal of radiation oncology, biology, physics, 2013-12-01

Practical radiation oncology, 2015

Practical radiation oncology, 2017

Frontiers in oncology, 2017

International journal of radiation oncology, biology, physics, 2008-09-01

Endocr. Relat. Cancer, 2018 Nov 23

Clin Nucl Med,

J. Nucl. Med., 2017 Jun 21

International journal of radiation oncology, biology, physics, 2015-06-01

American journal of clinical oncology, 1991-04

Surgery, 2012-12

Annals of surgical oncology, 2018-07


J Clin Endocrinol Metab, 2006 Aug 08

J Cancer Res Ther,

J Clin Endocrinol Metab,

Radiat Oncol, 2017-03-09

Lancet, 2019 Jun 18

The Lancet. Oncology, 2018-11

Lancet Oncol, 2019 Sep 17

Int. J. Radiat. Oncol. Biol. Phys., 2017 Jan 06

Adv Radiat Oncol, 2019 Apr 04

European urology, 2018-07

Radiother Oncol, 2022 Feb 18

International journal of radiation oncology, biology, physics, 2008-04-01

International journal of radiation oncology, biology, physics, 2014-07-01

International journal of radiation oncology, biology, physics, 2016-07-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Frontiers of radiation therapy and oncology, 2011

Current urology reports, 2017-07

Radiother Oncol, 2020 Jul 11

Semin Radiat Oncol, 2016 Aug 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

Anticancer research, 2014-12

Clinical genitourinary cancer, 2018-08

Eur. J. Cancer, 2012 Mar 08

Cancer, 1978-12

The Lancet. Oncology, 2007-01

Radiother Oncol, 2015 Dec 15

Urology, 2013-06

International journal of radiation oncology, biology, physics, 2018-06-01

JAMA surgery, 2018-01-17

Radiother Oncol, 2015 Mar 11

Clin Oncol (R Coll Radiol), 2017 Feb 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

N. Engl. J. Med., 2019 Jun 02

J. Clin. Oncol., 2015 May 26

J. Clin. Oncol.,

N. Engl. J. Med.,

The Journal of urology, 2004-10

Eur. J. Cancer,

International journal of radiation oncology, biology, physics, 1992

J. Urol.,

BMC Cancer, 2011 Jul 14

Practical radiation oncology, 2018

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

Nucl Med Mol Imaging, 2016 Aug 06

Int. J. Oncol., 2012 Oct 04

Urology, 1996-08

Eur. J. Nucl. Med. Mol. Imaging, 2017 Apr 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20

Nat Rev Urol, 2014 Apr

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

Int. J. Radiat. Oncol. Biol. Phys.,

Clin Oncol (R Coll Radiol), 2014 Nov 01

N. Engl. J. Med., 2018 Jun 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-20

International journal of radiation oncology, biology, physics, 2012-04-01

Cancer, 2022 Apr 05

Nature, 2013-07-11

The New England journal of medicine, 2015-10-29


N Engl J Med, 2010 Jul 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10


Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-03-15

The Lancet. Oncology, 2016-03

European urology, 2016-05

Clinical genitourinary cancer, 2017-12

Prostate Int,

Practical radiation oncology, 2018

Practical radiation oncology, 2018

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Nat Rev Urol, 2017 Dec 12

International journal of radiation oncology, biology, physics, 2008-01-01

Frontiers in oncology, 2014

The Journal of urology, 2004-03

International journal of radiation oncology, biology, physics, 2018-10-01

Radiation oncology (London, England), 2012-02-16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-07

Journal of contemporary brachytherapy, 2016-10

International journal of radiation oncology, biology, physics, 2012-07-01

Radiother Oncol, 2009 Apr

Radiat Oncol, 2018 Mar 20

Lancet, 2021 Dec 23

Clinical radiology, 2008-04

AJR Am J Roentgenol,

The New England journal of medicine, 2017-07-27

Ann. Oncol.,

International journal of radiation oncology, biology, physics, 2012-11-15

International journal of radiation oncology, biology, physics, 2011-11-15

Brachytherapy, 2014

Urology, 2013-02

J. Urol., 2012 Jan 20

International journal of radiation oncology, biology, physics, 2018-11-01

JAMA, 2017-09-12

Cancer, 2013-01-01

International journal of radiation oncology, biology, physics, 2007-09-01


J Clin Oncol, 2016 Feb 29

J Clin Oncol, 2020 Sep 11

The Lancet. Oncology, 2013-08

Eur Urol, 2017 Oct 23

J Clin Oncol, 2017 Jul 28

International journal of radiation oncology, biology, physics, 2017-06-01

Lancet Oncol., 2018 Dec 19

Radiother Oncol, 2020 Apr 01

J Clin Oncol, 2021 Jan 26

Int J Radiat Oncol Biol Phys, 2021 Sep 01

N. Engl. J. Med., 2019 May 31

J. Clin. Oncol., 2019 Jul 22

Lancet Oncol, 2019 Apr 12

Journal for immunotherapy of cancer, 2018-01-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-04

Semin Radiat Oncol, 2004-01-01

Practical radiation oncology, 2017

The Lancet. Oncology, 2016-07

AJR. American journal of roentgenology, 2019-10

JAMA oncology, 2019-06-01

Clin Nucl Med,

The New England journal of medicine, 2018-04-05

Ann. Oncol., 2013 Nov 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-01-01

Eur. Urol., 2020 Jan 17

The Lancet. Oncology, 2016-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Lancet, 2019 Apr 11

Practical radiation oncology, 2015

Physics in medicine and biology, 2006-10-07

Lancet Oncol., 2013 Jan 08

Practical radiation oncology, 2017

Abdominal radiology (New York), 2019-01

Journal of endourology, 2019-10

J Endourol,

Advances in radiation oncology, 2021 May 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-01

The Lancet. Oncology, 2015-11

Ann Oncol,

Cancer, 2020 Sep 25

Clin Cancer Res, 2018 Oct 16

The Lancet. Oncology, 2019-03

JAMA Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-20

Br. J. Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-04

The New England journal of medicine, 2019-03-21

Annals of surgery, 2007-10

Annals of surgery, 2012-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

Urol. Int., 2012 Dec 13

Lancet Oncol., 2019 Jul 10

International journal of radiation oncology, biology, physics, 2009-06-01

Urology, 2007-02

Case Rep Urol, 2013 May 08

Brachytherapy, 2014

J Contemp Brachytherapy, 2016 Dec 06

The New England journal of medicine, 2015-11-05

The New England journal of medicine, 2015-11-05

BJU international, 2012-10

European urology, 2018-08

N. Engl. J. Med., 2019 Sep 30


JAMA oncology, 2018-06-14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-12-20

Annals of oncology : official journal of the European Society for Medical Oncology, 2010-04

Sex Med Rev, 2019 Jul 24

Eur. Urol., 2018 Jul 03

Seminars in radiation oncology, 2017-07

The New England journal of medicine, 2003-08-28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20


Cancer, 2012 Jan 03

JAMA Oncol, 2018 Nov 1

J. Clin. Oncol., 2017 Dec 14

Eur. Urol., 2019 Jul 19

The Lancet. Oncology, 2017-11

Ann. Oncol.,

J. Clin. Oncol., 2011 Dec 12

European urology focus, 2019-11

Obstet Gynecol, 2009-09-01

Prostate cancer and prostatic diseases, 2019-12

International journal of radiation oncology, biology, physics, 2008-03-01

JAMA, 2012-04-18

Cancer, 2014-04-01

Int. J. Radiat. Oncol. Biol. Phys.,

J. Infect. Chemother., 2013 May 04

Cochrane Database Syst Rev, 2011 May 11

J. Clin. Oncol.,